JP2017512202A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512202A5
JP2017512202A5 JP2016554261A JP2016554261A JP2017512202A5 JP 2017512202 A5 JP2017512202 A5 JP 2017512202A5 JP 2016554261 A JP2016554261 A JP 2016554261A JP 2016554261 A JP2016554261 A JP 2016554261A JP 2017512202 A5 JP2017512202 A5 JP 2017512202A5
Authority
JP
Japan
Prior art keywords
composition
sequence
cholesterol
nucleic acid
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554261A
Other languages
English (en)
Japanese (ja)
Other versions
JP6772065B2 (ja
JP2017512202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/054131 external-priority patent/WO2015128461A1/en
Publication of JP2017512202A publication Critical patent/JP2017512202A/ja
Publication of JP2017512202A5 publication Critical patent/JP2017512202A5/ja
Application granted granted Critical
Publication of JP6772065B2 publication Critical patent/JP6772065B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554261A 2014-02-28 2015-02-27 免疫賦活プラスミド Expired - Fee Related JP6772065B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946372P 2014-02-28 2014-02-28
US61/946,372 2014-02-28
PCT/EP2015/054131 WO2015128461A1 (en) 2014-02-28 2015-02-27 Immunostimulatory plasmids

Publications (3)

Publication Number Publication Date
JP2017512202A JP2017512202A (ja) 2017-05-18
JP2017512202A5 true JP2017512202A5 (enExample) 2018-04-05
JP6772065B2 JP6772065B2 (ja) 2020-10-21

Family

ID=52598746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554261A Expired - Fee Related JP6772065B2 (ja) 2014-02-28 2015-02-27 免疫賦活プラスミド

Country Status (20)

Country Link
US (2) US10155950B2 (enExample)
EP (1) EP3110940A1 (enExample)
JP (1) JP6772065B2 (enExample)
KR (1) KR20160122849A (enExample)
CN (1) CN106029867B (enExample)
AU (1) AU2015222102B2 (enExample)
BR (1) BR112016019837A2 (enExample)
CA (1) CA2940794C (enExample)
CL (1) CL2016002146A1 (enExample)
CR (1) CR20160393A (enExample)
DO (1) DOP2016000223A (enExample)
IL (1) IL247065A0 (enExample)
MX (1) MX2016010993A (enExample)
PE (1) PE20170404A1 (enExample)
PH (1) PH12016501705A1 (enExample)
RU (1) RU2740492C2 (enExample)
SV (1) SV2016005263A (enExample)
UA (1) UA118374C2 (enExample)
WO (1) WO2015128461A1 (enExample)
ZA (1) ZA201605495B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016019837A2 (pt) * 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3313376A2 (en) * 2015-06-26 2018-05-02 Bayer Animal Health GmbH Methods of modulating cytosolic dna surveillance molecules
DK3328423T3 (da) * 2015-07-31 2021-07-26 Bayer Animal Health Gmbh Forbedret immunrespons hos fisk
CN108025062A (zh) * 2015-07-31 2018-05-11 拜耳动物保健有限责任公司 猪科动物物种中增强的免疫应答
CR20190037A (es) * 2016-07-26 2019-05-16 Bayer Animal Health Gmbh Aumento de la fertilidad en especies bovinas
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR20250048594A (ko) * 2017-12-15 2025-04-09 엘랑코 애니멀 헬스 게엄베하 면역자극성 올리고뉴클레오티드
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
DE60039198D1 (de) 1999-03-26 2008-07-24 Vical Inc Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
US20040002472A1 (en) 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
US6517218B2 (en) 2000-03-31 2003-02-11 Relume Corporation LED integrated heat sink
MXPA03009626A (es) 2001-04-24 2004-06-30 Innogenetics Nv Construcciones y metodo para la expresion de proteinas recombinantes de la envoltura viral de hcv.
MXPA03011924A (es) 2001-07-02 2004-03-26 Pfizer Prod Inc Vacuna de micoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado.
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
DK1605971T3 (da) 2003-03-26 2010-08-16 Wyeth Llc Immunogene sammensætninger og fremgangsmåder
WO2005034979A2 (en) 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20060135457A1 (en) * 2004-08-13 2006-06-22 Yvonne Paterson Methods for constructing antibiotic resistance free vaccines
US20090068223A1 (en) 2005-11-15 2009-03-12 Boehringer Ingelheim Vetmedica, Inc. Combination vaccine comprising an attenuated bovine viral diarrhea virus
TWM297441U (en) 2006-03-30 2006-09-11 Cheng-Jiun Jian LED projection light source module
US7663229B2 (en) 2006-07-12 2010-02-16 Hong Kong Applied Science And Technology Research Institute Co., Ltd. Lighting device
CA2664308A1 (en) * 2006-10-06 2008-05-08 The Scripps Research Institute Dna composition for eliciting an immune response against tumor-associated macrophages
US8470560B2 (en) * 2007-10-03 2013-06-25 The United States Of America As Represented By The Secretary Of The Army CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
JP5759890B2 (ja) 2008-03-25 2015-08-05 ジュバリス・バイオセラピューティクス・インコーポレイテッドＪｕｖａｒｉｓ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． カチオン性脂質−ｄｎａ複合体（ｃｌｄｃ）の投与による免疫応答の増強
CA2740954C (en) 2008-10-31 2018-09-25 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine composition
DK2992899T3 (da) 2009-05-14 2020-09-14 Bayer Ip Gmbh Forøget immunrespons hos fuglearter
LT2654785T (lt) 2010-12-22 2019-07-10 Bayer Intellectual Property Gmbh Sustiprintas galvijų imuninis atsakas
CL2011000065A1 (es) 2011-01-11 2011-04-15 Univ Concepcion Formulacion veterinaria para la prevencion y eliminacion de infeccion por cepas de e. coli stec, que comprende un plasmido recombinante que codifica un factor de virulencia y liposoma cationico como vehiculo, uso de dicha formulacion para tratar preferentemente bovinos y porcinos.
BR112016019837A2 (pt) * 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores

Similar Documents

Publication Publication Date Title
JP2017512202A5 (enExample)
RU2016138321A (ru) Иммуностимулирующие плазмиды
JP7523897B2 (ja) 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン
Schwendener Liposomes as vaccine delivery systems: a review of the recent advances
JP4294584B2 (ja) 核酸ワクチン接種の免疫応答を高めるための方法
RU2013133730A (ru) Повышение иммунного отклика у видов крупного рогатого скота
JP2014522842A5 (enExample)
JP2014520807A5 (enExample)
CN101616687B (zh) 非特异性免疫刺激剂
WO2021236980A1 (en) Coronavirus antigen compositions and their uses
MXPA05013746A (es) Conjugados de esfingoide-polialquilamina para vacunacion.
CN116406299A (zh) 用于递送mRNA疫苗的脂质纳米颗粒
EP4091630A1 (en) Vaccines comprising r-dotap
Garulli et al. Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo
RU2014135522A (ru) Промоторы для увеличенной экспрессии белка у менингококка
JP2018518511A5 (enExample)
RU2018102915A (ru) Способы модуляции контрольных молекул цитозольной днк
US11111277B2 (en) Influenza vaccines
Lee et al. Perspective of peptide vaccine composed of epitope peptide, CpG-DNA, and liposome complex without carriers
Tomai et al. TLR agonists as vaccine adjuvants
AR105568A1 (es) Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina
US20230181722A1 (en) Coronavirus antigen compositions and their uses
EP3035960A2 (en) Respiratory syncytial virus (rsv) vaccine
US20240316178A1 (en) Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereof
HK40083470A (en) Vaccines comprising r-dotap